ANDA 202590, held by Avet Lifesciences. Levofloxacin.
As of Nov 16, 2026, ANDA 202590 (Levofloxacin), held by Avet Lifesciences, was first approved by FDA on Jan 24, 2013, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 24, 2013 | Original application | Approved | None posted |
| LevofloxacinEQ 500MG/20ML (EQ 25MG/ML) · injectable;injection | Levofloxacin | Discontinued |
| LevofloxacinEQ 750MG/30ML (EQ 25MG/ML) · injectable;injection | Levofloxacin | Discontinued |
| Sep 20, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jan 11, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 3, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 17, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 18, 2018 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 14, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 14, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 24, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters